Drug Trial Radar · NCT04885530
ACTIV-6: COVID-19 Study of Repurposed Medications
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,956
Actual
Start
Jun 8, 2021
Primary completion
Apr 29, 2024
Study completion Apr 29, 2024
Sponsor
- Lead sponsor
- Susanna Naggie, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
- First posted
- May 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID. Pro00107921\_A - Arm D (Ivermectin 400) - NCT05736861; Pro00107921\_B - Arm B (Fluvoxamine) - NCT05890586; Pro00107921\_C - Arm C (Fluticasone) - NCT05736874; Pro00107921\_D - Arm D (Ivermectin 600) - NCT05894538; Pro00107921\_E - Arm E (Fluvoxamine 100) - NCT05894564; Pro00107921\_F - Arm F (Montelukast) - NCT05894577; Pro00107921\_G - Arm G (Metformin) - NCT06042855.
Conditions
- Covid19
Interventions
IvermectinDrug
Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with "123" over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
FluvoxamineDrug
Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has "APO" and the other side has "F50" with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
FluticasoneDrug
Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
PlaceboOther
Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
MontelukastDrug
Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
MetforminDrug
Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Participants Randomized Within Each AppendixTime frame: Up to approximately 2 years 10 months
Locations
110 sites in 1 country. Site status is shown where the registry gives one.
Chandler Regional Medical Center
Chandler, Arizona
Lamb Health, LLC
Gilbert, Arizona
First Care Medical Clinic
Mesa, Arizona
Trident Health Center
Peoria, Arizona
University of Arkansas Medical Sciences
Little Rock, Arkansas
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Assuta Family Medical Group APMC
North Hollywood, California
Stanford
Palo Alto, California
Olive View - UCLA Medical Center
Sylmar, California
Doctors Medical Group of Colorado Springs, P.C.
Colorado Springs, Colorado
Pine Ridge Family Medicine Inc.
Colorado Springs, Colorado
Tabitha B. Fortt, M.D., LLC
Stamford, Connecticut
George Washington University Hospital
Washington D.C., District of Columbia
Arena Medical Group
Deerfield Beach, Florida
Lupus Foundation of Gainesville
Gainesville, Florida
University of Florida Health
Gainesville, Florida
L and A Morales Healthcare, Inc
Hialeah, Florida
University of Florida-JAX-ASCENT
Jacksonville, Florida
AMRON Vitality and Wellness Center, LLC
Jacksonville, Florida
Sunshine Walk In Clinic
Lake Mary, Florida
Lakeland Regional Medical Center
Lakeland, Florida
Jackson Memorial Hospital
Miami, Florida
University of Miami
Miami, Florida
Well Pharma Medical Research
Miami, Florida
The Angel Medical Research Corporation
Miami Lakes, Florida
Innovation Clinical Trials Inc.
Palmetto Bay, Florida
Lice Source Services Plantation
Plantation, Florida
Premier Health
St. Petersburg, Florida
Tallahassee Memorial Hospital
Tallahassee, Florida
Tampa General Hospital
Tampa, Florida
UF Health Precision Health Research
The Villages, Florida
Morehouse School of Medicine
Atlanta, Georgia
Emory Healthcare
Atlanta, Georgia
Essential Medical Care, Inc.
College Park, Georgia
Clincept, LLC
Columbus, Georgia
HOPE Clinical Research and Wellness
Conyers, Georgia
David Kavtaradze MD, Inc.
Cordele, Georgia
Elite Family Practice
Douglasville, Georgia
Christ the King Health Care, P.C.
Loganville, Georgia
Miller Family Practice, LLC
Macon, Georgia
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.